Largest Real World Dataset of Immune Checkpoint Inhibitors in Melanoma Treatment Demonstrates Similar Outcomes to Randomised Clinical Trials
Rapid treatment uptake and similar outcomes in patients with metastatic melanoma.
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1553 results
Real-World Data Validation of Association Between Immunoregulatory Molecules Expression and Targetable Cancer Genes
Looking into future design of clinical trials in a tissue-agnostic fashion
WHO Estimation of Cervical Cancer Mortality
Results from a comparative modelling analysis in low-income and lower-middle-income countries
Talazoparib Shows Encouraging Antitumour Activity in Docetaxel Pretreated mCRPC
TALAPRO-1 results in pretreated patients with metastatic castration-resistant prostate cancer
Restrictions in Use of Cyproterone Due to Meningioma Risk
The risk increases with increasing cumulative doses of cyproterone acetate
Cervical Cancer Elimination in Low-Income and Lower-Middle-Income Countries
Impact of HPV vaccination and cervical screening
Colorectal Cancer in Ulcerative Colitis and Crohn’s Disease
Findings from a Scandinavian population-based cohort study
HPV Vaccine Hesitancy
Many deaths could still be prevented if vaccination coverage is restored
Treatment of Helicobacter Pylori Infection May Reduce the Risk of Gastric Cancer in First-Degree Relatives of Patients with Gastric Cancer
Findings from a prospective, double-blind, placebo-controlled trial conducted in South Korea
Angiosarcoma Project
Patient-partnered research approach
Treatment with CAR-NK Cells in Patients with Relapsed or Refractory CD19-positive Lymphoid Tumours
Preliminary results of use of CAR-transduced natural killer cells
EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab
Ruxience is a biosimilar, highly similar to the reference product MabThera, which was authorised in the EU in 1998